Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Routine Surveillance

ABSTRACT: Strain from routine IMD surveillance in Belgium

PROVIDER: PRJEB37139 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR3981059_1.fastq.gz	Fastqsanger.gz
	ERR3981059_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 2 of 2

Similar Datasets

Strain from routine IMD surveillance in Belgium

Project description:Strain from routine IMD surveillance in Belgium

| PRJEB45732 | ENA

IMD surveillance Belgium

Project description:Strains from routine IMD surveillance Belgium

| PRJEB46584 | ENA

Molecular surveillance of STEC

Project description:Routine surveillance of STEC at the Belgian NRC STEC

| PRJEB54005 | ENA

NGS data for Salmonella Surveillance in Belgium

Project description:NGS data for Salmonella Surveillance in Belgium

| PRJEB41015 | ENA

Project description:Routine Surveillance

| PRJNA1006559 | ENA

Genomic Grade Index (GGI): Feasibility in routine practice and impact on treatment decisions in early breast cancer

Project description:Genomic Grade Index (GGI) is a 97-gene signature that improves histologic grade (HG) classification in invasive breast carcinoma. In this prospective study we sought to evaluate the feasibility of performing GGI in routine clinical practice and its impact on treatment recommendations. Patients with pT1pT2 or operable pT3, N0-3 invasive breast carcinoma were recruited from 8 centers in Belgium. Fresh surgical samples were sent at room temperature in the MapQuant Dx™ PathKit for centralized genomic analysis. Genomic profiles were determined using Affymetrix U133 Plus 2.0 and GGI calculated using the MapQuant Dx™ protocol, which defines tumors as low or high Genomic Grade (GG-1 and GG-3 respectively). 180 pts were recruited and 155 were eligible. The MapQuant test was performed in 142 cases and GGI was obtained in 78% of cases (n=111). Reasons for failures were 15 samples with <30% of invasive tumor cells (11%), 15 with insufficient RNA quality (10%), and 1 failed hybridization (<1%). For tumors with an available representative sample (≥ 30% inv. tumor cells) (n=127), the success rate was 87.5 %. GGI reclassified 69% of the 54 HG2 tumors as GG-1 (54%) or GG-3 (46%). Changes in treatment recommendations occurred mainly in the subset of HG2 tumors reclassified into GG-3, with increased use of chemotherapy in this subset. The use of GGI is feasible in routine clinical practice and impacts treatment decisions in early-stage breast cancer.

2013-06-03 | GSE43365 | GEO

Oncogenic CDK13 Mutations Impede Nuclear RNA Surveillance

Project description:RNA surveillance pathways detect and degrade defective transcripts to ensure RNA fidelity. We find disrupted nuclear RNA surveillance is oncogenic. Cyclin Dependent Kinase 13 (CDK13) is mutated in melanoma and patient-mutated CDK13 accelerates zebrafish melanoma. CDK13 mutation causes aberrant RNA stabilization. CDK13 is required for ZC3H14 phosphorylation, which is necessary and sufficient to promote nuclear RNA degradation. Mutant CDK13 fails to activate nuclear RNA surveillance, causing aberrant protein-coding transcripts to be stabilized and translated. Forced aberrant RNA expression accelerates melanoma in zebrafish. We find recurrent mutations in genes encoding nuclear RNA surveillance components in many malignancies, establishing nuclear RNA surveillance as a tumor-suppressive pathway. Activating nuclear RNA surveillance is crucial to avoid accumulation of aberrant RNAs and their ensuing consequences in development and disease.

2023-04-21 | GSE131334 | GEO

2022: routine sample from the IIMK

Project description:2022: routine sample from the IIMK

| PRJEB59013 | ENA

2023: routine sample from the IIMK

Project description:2023: routine sample from the IIMK

| PRJEB78597 | ENA

Oncogenic CDK13 Mutations Impede Nuclear RNA Surveillance (zfChIPseq)

2023-04-21 | GSE131332 | GEO